A Published Study Shows the Potential of microRNAs to be Used as Biomarkers for Diagnosing the Primary Tumor Site in Patients With Cancer of Unknown
Primary (CUP) Rosetta Genomics is Currently Developing a Technology That Will be the
Basis of a CUP Diagnostic Test That Will be Submitted for Regulatory
Approval by a CLIA-certified lab in the US in 2008 Approximately 70,000 Patients in the US are Diagnosed With CUP Each Year Only After Several Tests Have Failed to Identify the Origin of the Cancer; Accurate Diagnosis for CUP can be Critical in Determining Optimal Treatment
REHOVOT, Israel and JERSEY CITY, New Jersey, March 24 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDAQ: ROSG), announced today that the results of a research study, conducted by its scientists and collaborators and describing the use of microRNAs in accurately identifying tumor origin, have been published in Nature Biotechnology. . The study findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients with cancer of unknown primary (CUP). Rosetta Genomics is currently developing a technology that will be the basis of a CUP diagnostic tests that will be submitted by a CLIA certified lab in the US in 2008..
"Accurately identifying the origin of a metastasis in CUP patients can
be critical for determining appropriate treatment, and currently presents a
true unmet diagnostic need for patients and physicians," said Amir Avniel,
President and CEO of Rosetta Genomics. "This research demonstrates the
tremendous potential of microRNAs as e
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved